A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 154,163 shares of BMRN stock, worth $10.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
154,163
Previous 545,096 71.72%
Holding current value
$10.3 Million
Previous $44.9 Million 75.85%
% of portfolio
0.03%
Previous 0.12%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$69.02 - $93.84 $27 Million - $36.7 Million
-390,933 Reduced 71.72%
154,163 $10.8 Million
Q2 2024

Jul 29, 2024

SELL
$74.43 - $92.22 $18.8 Million - $23.3 Million
-252,669 Reduced 31.67%
545,096 $44.9 Million
Q1 2024

May 08, 2024

BUY
$83.81 - $99.0 $39.1 Million - $46.2 Million
466,544 Added 140.86%
797,765 $69.7 Million
Q4 2023

Feb 09, 2024

SELL
$76.22 - $98.51 $19.6 Million - $25.4 Million
-257,722 Reduced 43.76%
331,221 $31.9 Million
Q3 2023

Nov 13, 2023

BUY
$85.07 - $94.48 $34 Million - $37.8 Million
400,055 Added 211.79%
588,943 $52.1 Million
Q2 2023

Aug 08, 2023

BUY
$86.68 - $100.3 $778,733 - $901,095
8,984 Added 4.99%
188,888 $16.4 Million
Q1 2023

May 08, 2023

BUY
$87.74 - $117.27 $6.05 Million - $8.09 Million
68,965 Added 62.16%
179,904 $17.5 Million
Q4 2022

Feb 09, 2023

SELL
$80.93 - $108.63 $4.88 Million - $6.55 Million
-60,275 Reduced 35.2%
110,939 $11.5 Million
Q3 2022

Nov 10, 2022

SELL
$82.16 - $96.94 $3.15 Million - $3.72 Million
-38,380 Reduced 18.31%
171,214 $14.5 Million
Q2 2022

Aug 04, 2022

SELL
$71.48 - $86.85 $413,511 - $502,427
-5,785 Reduced 2.69%
209,594 $17.4 Million
Q1 2022

May 12, 2022

BUY
$74.28 - $92.69 $1.92 Million - $2.39 Million
25,833 Added 13.63%
215,379 $16.6 Million
Q4 2021

Feb 09, 2022

BUY
$71.72 - $91.47 $159,218 - $203,063
2,220 Added 1.19%
189,546 $16.7 Million
Q3 2021

Nov 08, 2021

BUY
$74.77 - $85.47 $2.63 Million - $3 Million
35,133 Added 23.08%
187,326 $14.5 Million
Q2 2021

Aug 05, 2021

BUY
$75.51 - $84.79 $797,687 - $895,721
10,564 Added 7.46%
152,193 $12.7 Million
Q1 2021

May 05, 2021

BUY
$74.73 - $90.69 $854,014 - $1.04 Million
11,428 Added 8.78%
141,629 $10.7 Million
Q4 2020

Feb 12, 2021

SELL
$72.61 - $90.2 $2.86 Million - $3.56 Million
-39,447 Reduced 23.25%
130,201 $11.4 Million
Q3 2020

Nov 09, 2020

BUY
$71.87 - $131.03 $5.29 Million - $9.64 Million
73,578 Added 76.59%
169,648 $12.9 Million
Q2 2020

Aug 04, 2020

SELL
$79.55 - $124.22 $3.74 Million - $5.83 Million
-46,963 Reduced 32.83%
96,070 $11.8 Million
Q1 2020

May 12, 2020

SELL
$71.37 - $96.85 $204,903 - $278,056
-2,871 Reduced 1.97%
143,033 $12.1 Million
Q4 2019

Feb 11, 2020

BUY
$64.27 - $86.37 $962,314 - $1.29 Million
14,973 Added 11.44%
145,904 $12.3 Million
Q3 2019

Nov 12, 2019

BUY
$67.4 - $85.11 $840,815 - $1.06 Million
12,475 Added 10.53%
130,931 $8.83 Million
Q2 2019

Aug 02, 2019

SELL
$80.35 - $93.9 $2.27 Million - $2.66 Million
-28,282 Reduced 19.27%
118,456 $10.1 Million
Q1 2019

Apr 26, 2019

BUY
$84.2 - $98.62 $3.28 Million - $3.84 Million
38,968 Added 36.16%
146,738 $13 Million
Q4 2018

Feb 13, 2019

SELL
$80.14 - $106.07 $1.81 Million - $2.39 Million
-22,557 Reduced 17.31%
107,770 $9.01 Million
Q3 2018

Nov 13, 2018

SELL
$93.92 - $105.72 $14.1 Million - $15.9 Million
-150,451 Reduced 53.58%
130,327 $12.6 Million
Q2 2018

Aug 01, 2018

SELL
$76.01 - $99.03 $651,101 - $848,290
-8,566 Reduced 2.96%
280,778 $26.4 Million
Q1 2018

May 07, 2018

BUY
$77.67 - $92.63 $293,204 - $349,678
3,775 Added 1.32%
289,344 $23.5 Million
Q4 2017

Feb 01, 2018

BUY
$80.76 - $95.13 $5.14 Million - $6.05 Million
63,631 Added 28.67%
285,569 $25.5 Million
Q3 2017

Nov 02, 2017

BUY
$80.6 - $94.95 $17.9 Million - $21.1 Million
221,938
221,938 $20.7 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.